• Sunshine Biopharma Inc SBFM.OQ reported a quarterly adjusted loss of 39 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-9.94. The lone analyst forecast for the quarter was for a loss of 11 cents per share.

• Revenue rose 1.2% to $9.41 million from a year ago; analysts expected $11.20 million.

• Sunshine Biopharma Inc's reported EPS for the quarter was a loss of 39 cents​.

• The company reported a quarterly loss of $1.77 million.

• Sunshine Biopharma Inc shares had risen by 4.2% this quarter and lost 50.0% so far this year.

FORECAST CHANGES

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Sunshine Biopharma Inc is $7.00, about 78.6% above its last closing price of $1.50

This summary was machine generated from LSEG data August 14 at 09:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)